關(guān)鍵詞

奧希替尼 CD19 腫瘤免疫 tau蛋白 猴痘 泰朗妥昔單抗 HIV 卡替拉韋 澤布替尼 奧妥珠單抗

?

#今日行業(yè)熱點(diǎn)#

①The New England Journal of Medicine：Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

臨床試驗(yàn)分析：奧希替尼（Osimertinib）用于完全切除的、表皮生長(zhǎng)因子受體(EGFR)突變的非小細(xì)胞肺癌(NSCLC)的總生存率

DOI: 10.1056/NEJMoa2304594

②The New England Journal of Medicine：Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

結(jié)果分析：接受CD19特異性CAR-T細(xì)胞策略(axi-cel)用于復(fù)發(fā)或難治性大B細(xì)胞淋巴瘤的生存率

DOI: 10.1056/NEJMoa2301665

③Cancer Immunology Research：Clec4A4 Acts As A Negative Immune Checkpoint Regulator to Suppress Antitumor Immunity

C型凝集素受體Clec4A4作為負(fù)性免疫檢查點(diǎn)調(diào)節(jié)因子抑制抗腫瘤免疫

DOI: 10.1158/2326-6066.CIR-22-0536

④JCI Insight：A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases

一種非耗竭性、高親和力的抗人CD19抗體具有強(qiáng)效的B細(xì)胞抑制活性及其用于自身免疫性疾病的潛力

DOI: 10.1172/jci.insight.166137

⑤Expert Opinion on Investigational Drugs ：Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

綜述：基于被動(dòng)tau蛋白的免疫策略及原發(fā)性和繼發(fā)性tau蛋白病的臨床進(jìn)展和挑戰(zhàn)

DOI: 10.1080/13543784.2023.2233892

⑥Acta Neuropathologica Communications：Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo

用抗體靶向TDP-43的富甘氨酸結(jié)構(gòu)域可防止其在體外聚集，并降低體內(nèi)神經(jīng)絲水平

DOI: 10.1186/s40478-023-01592-z

⑦國(guó)內(nèi)首款“復(fù)制缺陷型猴痘疫苗”臨床試驗(yàn)申請(qǐng)獲CDE受理

⑧抗體偶聯(lián)藥物（ADC）泰朗妥昔單抗（Loncastuximab tesirine）上市申請(qǐng)已獲受理，用于復(fù)發(fā)/難治性彌漫性大B細(xì)胞淋巴瘤（R/R DLBCL）

⑨HIV整合酶鏈轉(zhuǎn)移抑制劑（INSTI）卡替拉韋獲國(guó)家藥監(jiān)局批準(zhǔn)上市，用于HIV-1感染及HIV的暴露前預(yù)防

⑩BTK抑制劑澤布替尼聯(lián)合奧妥珠單抗用于復(fù)發(fā)或難治性（R/R）濾泡性淋巴瘤（FL）的適應(yīng)癥上市申請(qǐng)獲FDA受理

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴(lài)的合作伙伴！